Browse by Series:

Managing Avelumab Side Effects in Patients With Merkel Cell Carcinoma

Howard Kaufman, MD
Published: Thursday, May 04, 2017



Howard L. Kaufman, MD, FACS, chief surgical officer and associate director for clinical science at Rutgers Cancer Institute of New Jersey, discusses the adverse event profile of avelumab (Bavencio) for patients with Merkel cell carcinoma.
Slider Left
Slider Right


Howard L. Kaufman, MD, FACS, chief surgical officer and associate director for clinical science at Rutgers Cancer Institute of New Jersey, discusses the adverse event profile of avelumab (Bavencio) for patients with Merkel cell carcinoma.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x